Cambrian Bio, a US-based clinical-stage biotechnology company, announced on Tuesday that it has introduced its new pipeline company, Amplifier Therapeutics.

The new pipeline company is to develop ATX-304, a pan-AMPK (AMP-activated protein kinase) activator.

Amplifier has acquired Betagenon AB, a Swedish biopharmaceutical company, which has discovered novel AMPK activators and will continue development as a part of the Amplifier team.

James Hall, MD, PhD is to head Amplifier Therapeutics. He joined as the CEO of Betagenon AB in 2021 and was earlier the head of Cardiovascular Business Development at AstraZeneca.